HK Stock Movement | KEYMED BIO-B (02162) Rises Over 3% Against Market Trend as CM512 Phase I Trial for Atopic Dermatitis Meets All Endpoints

Stock News11-05

KEYMED BIO-B (02162) surged over 3% against the broader market trend, reaching HK$64.25 with a trading volume of HK$49.02 million by press time.

The company announced on November 4 that its self-developed CM512, the world's first long-acting TSLP x IL-13 bispecific antibody, achieved all primary endpoints in its Phase I clinical trial for moderate-to-severe atopic dermatitis (AD) in adults.

Clinical data demonstrated CM512's rapid disease control, deep remission, and sustained efficacy in treating moderate-to-severe AD patients, with a favorable safety profile and an extended half-life of 70 days. These results suggest its potential as a best-in-class therapy for adult AD.

CM512 is KEYMED BIO's proprietary IgG-like bispecific antibody that simultaneously targets TSLP and IL-13. It works by early suppression of inflammatory cascade initiation, effectively reducing Th2 cell differentiation and IL-13 cytokine release while directly inhibiting IL-13-driven pathological symptoms, offering enhanced treatment for type 2 inflammatory diseases.

The company is accelerating Phase II trials for CM512 across multiple indications including AD, chronic rhinosinusitis with nasal polyps, asthma, chronic obstructive pulmonary disease, and chronic spontaneous urticaria.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1105079913?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 10:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105079913","market":"fut","top_or_hot":-1,"title":"HK Stock Movement | KEYMED BIO-B (02162) Rises Over 3% Against Market Trend as CM512 Phase I Trial for Atopic Dermatitis Meets All Endpoints","media":"Stock News","content":"<p>KEYMED BIO-B (02162) surged over 3% against the broader market trend, reaching HK$64.25 with a trading volume of HK$49.02 million by press time.</p>\n<p>The company announced on November 4 that its self-developed CM512, the world's first long-acting TSLP x IL-13 bispecific antibody, achieved all primary endpoints in its Phase I clinical trial for moderate-to-severe atopic dermatitis (AD) in adults.</p>\n<p>Clinical data demonstrated CM512's rapid disease control, deep remission, and sustained efficacy in treating moderate-to-severe AD patients, with a favorable safety profile and an extended half-life of 70 days. These results suggest its potential as a best-in-class therapy for adult AD.</p>\n<p>CM512 is KEYMED BIO's proprietary IgG-like bispecific antibody that simultaneously targets TSLP and IL-13. It works by early suppression of inflammatory cascade initiation, effectively reducing Th2 cell differentiation and IL-13 cytokine release while directly inhibiting IL-13-driven pathological symptoms, offering enhanced treatment for type 2 inflammatory diseases.</p>\n<p>The company is accelerating Phase II trials for CM512 across multiple indications including AD, chronic rhinosinusitis with nasal polyps, asthma, chronic obstructive pulmonary disease, and chronic spontaneous urticaria.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | KEYMED BIO-B (02162) Rises Over 3% Against Market Trend as CM512 Phase I Trial for Atopic Dermatitis Meets All Endpoints</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | KEYMED BIO-B (02162) Rises Over 3% Against Market Trend as CM512 Phase I Trial for Atopic Dermatitis Meets All Endpoints\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-05 10:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>KEYMED BIO-B (02162) surged over 3% against the broader market trend, reaching HK$64.25 with a trading volume of HK$49.02 million by press time.</p>\n<p>The company announced on November 4 that its self-developed CM512, the world's first long-acting TSLP x IL-13 bispecific antibody, achieved all primary endpoints in its Phase I clinical trial for moderate-to-severe atopic dermatitis (AD) in adults.</p>\n<p>Clinical data demonstrated CM512's rapid disease control, deep remission, and sustained efficacy in treating moderate-to-severe AD patients, with a favorable safety profile and an extended half-life of 70 days. These results suggest its potential as a best-in-class therapy for adult AD.</p>\n<p>CM512 is KEYMED BIO's proprietary IgG-like bispecific antibody that simultaneously targets TSLP and IL-13. It works by early suppression of inflammatory cascade initiation, effectively reducing Th2 cell differentiation and IL-13 cytokine release while directly inhibiting IL-13-driven pathological symptoms, offering enhanced treatment for type 2 inflammatory diseases.</p>\n<p>The company is accelerating Phase II trials for CM512 across multiple indications including AD, chronic rhinosinusitis with nasal polyps, asthma, chronic obstructive pulmonary disease, and chronic spontaneous urticaria.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"","article_id":"1105079913","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105079913","pubTimestamp":1762308495,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"KEYMED BIO-B (02162) surged over 3% against the broader market trend, reaching HK$64.25 with a trading volume of HK$49.02 million by press time. The company announced on November 4 that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B","BK1587":"次新股","BK1161":"生物科技","BK1574":"生物医药B类股","TSLP":"TSLA收益溢价策略ETF-Kurv","BK1583":"高瓴概念"},"translate_title":"港股动向|康康生物-B(02162)逆市涨超3%，CM512治疗特应性皮炎I期试验达到所有终点","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1,"TSLP":1},"content_text":"KEYMED BIO-B (02162) surged over 3% against the broader market trend, reaching HK$64.25 with a trading volume of HK$49.02 million by press time.\nThe company announced on November 4 that its self-developed CM512, the world's first long-acting TSLP x IL-13 bispecific antibody, achieved all primary endpoints in its Phase I clinical trial for moderate-to-severe atopic dermatitis (AD) in adults.\nClinical data demonstrated CM512's rapid disease control, deep remission, and sustained efficacy in treating moderate-to-severe AD patients, with a favorable safety profile and an extended half-life of 70 days. These results suggest its potential as a best-in-class therapy for adult AD.\nCM512 is KEYMED BIO's proprietary IgG-like bispecific antibody that simultaneously targets TSLP and IL-13. It works by early suppression of inflammatory cascade initiation, effectively reducing Th2 cell differentiation and IL-13 cytokine release while directly inhibiting IL-13-driven pathological symptoms, offering enhanced treatment for type 2 inflammatory diseases.\nThe company is accelerating Phase II trials for CM512 across multiple indications including AD, chronic rhinosinusitis with nasal polyps, asthma, chronic obstructive pulmonary disease, and chronic spontaneous urticaria.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1105079913","isCrawlerRequest":true}